MedPath

Neisseria meningitidis serogroup b nhba fusion protein antigen

Generic Name
Neisseria meningitidis serogroup b nhba fusion protein antigen
Brand Names
Bexsero
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
28E911Y7AE
Associated Conditions
Serogroup B Meningococcal Meningitis
Associated Therapies
-
pmlive.com
·

GSK granted EC approval for meningococcal disease vaccine Menveo

GSK’s fully liquid Menveo vaccine approved by EC for IMD protection in individuals aged two years and older, simplifying vaccination process without reconstitution, with comparable immunogenicity and safety to existing formulation. GSK committed to preventing bacterial meningitis in at-risk EU populations.
pharmaphorum.com
·

Alarm bell rings for GSK as US policy dents RSV jab sales

GSK's RSV vaccine Arexvy sales dropped 72% in Q3 due to narrower US recommendations and COVID-19 vaccination prioritization. Pfizer's Abrysvo sales declined only 5%, suggesting Pfizer's ascendency in the RSV vaccine market. GSK's overall vaccine sales fell 15%, leading to a revised forecast of low-single-digit percentage gains. Despite this, GSK's overall revenues increased 2% to $8 billion, supported by HIV drugs and specialty medicines.
finance.yahoo.com
·

20 Fastest Growing Health Tech Companies in the World

The digital health market, valued at $180.2 billion in 2023, is expected to grow to $549.7 billion by 2028, driven by technologies like mHealth, telehealth, and digital therapeutics. Key players include DexCom and Teladoc Health, with the US market leading at $88 billion in 2023. Telemedicine and wearable devices are pivotal, with the telemedicine market projected to reach $286.22 billion by 2030. Precision medicine and medical imaging technologies are also transforming healthcare, with companies like Merck & Co., Sanofi, and AstraZeneca leading in innovation and growth.
© Copyright 2025. All Rights Reserved by MedPath